Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada

Table 3 Case series data of the number of total/laryngeal HAE attacks in the year prior to initiating lanadelumab compared to the year following initiation of lanadelumab

Case	Pre-lanadelumab transition					Post-lanadelumab transition
Case	Attacks/year	Laryngeal attacks/year	Treated attacks/year	Missed work days/year	ISO	Attacks /year	Laryngeal attacks/year	Treated attacks/year	Missed work days/year	ISO
1	10	4	6	6	2	2	0	2	0	1
2	12	0	6	20	2	4	0	0	0	1
3	8	2	8	0	4	2	1	2	0	2
4	6	0	6	0	3	0	0	0	0	1
5	50	0	25	0	5	20	0	20	0	2
6	300	50	50	Off^a	5	100	40	40	Off^a	1
7	15	0	0	Off^b	4	12	0	0	Off^b	1
8	6	0	6	0	3	2	0	2	0	2
9	10	0	6	0	2	0	0	0	0	1
10	30	0	12	Retired	3	6	0	6	Retired	1
11	12	0	12	Off³	2	6	0	6	Off^c	1
12	3	0	3	Off⁴	3	0	0	0	Off^d	3

Treated attacks are the number of times an acute attack was treated with breakthrough therapy. ISO was determined from MD review of patient clinical encounter notes pre- and post-lanadelumab. ISO, impact on social outings (1 = no impact, 3 = some, 5 = a lot)
^aThis patient is unable to work due to the frequency of her attacks
^bThis patient is a homemaker and is not employed
^cThis patient is off work due to a prior motor vehicle accident in 1999 causing cervical stenosis and progressive myelopathy
^dThis patient is off work due to chronic comorbid medical conditions (T1DM, Adrenal Insufficiency)

ISSN: 1710-1492